2018 August 09 | Matthew H. Bailey, Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, Michael C. Wendl, Jaegil Kim, Brendan Reardon, Patrick Kwok-Shing Ng, Kang Jin Jeong, Song Cao, Zixing Wang, Jianjiong Gao, Qingsong Gao, Fang Wang, Eric Minwei Liu, Loris Mularoni, Carlota Rubio-Perez, Niranjan Nagarajan, Isidro Cortés-Ciriano, Daniel Cui Zhou, Wen-Wei Liang, Julian M. Hess, Venkata D. Yellapantula, David Tamborero, Abel Gonzalez-Perez, Chayaporn Suphavilai, Jia Yu Ko, Ekta Khurana, Peter J. Park, Eliezer M. Van Allen, Han Liang, The MC3 Working Group, The Cancer Genome Atlas Research Network, Michael S. Lawrence, Adam Godzik, Nuria Lopez-Bigas, Josh Stuart, David Wheeler, Gad Getz, Ken Chen, Alexander J. Lazar, Gordon B. Mills, Rachel Karchin, Li Ding
The authors of the article in Cell (2018) have corrected two errors in their manuscript. First, in the STAR Methods section, under the subheading "Hypermutators and Immune Infiltrates," they incorrectly referred to Figures S7A-S7C for data on sample stratification by hypermutator status. The correct reference is Figure S6A-S6C. Second, the lists of highly frequent missense mutations for COAD (colon adenocarcinoma) and READ (rectum adenocarcinoma) in Figure S7 were incorrect. The authors mistakenly combined the two cancer types in their initial analysis, despite them being listed separately in the figure. After reordering the mutations by frequency for each cancer type independently, the information has been updated in the revised Figure S7. These errors did not affect the major conclusions of the paper and have been corrected online. The authors apologize for any confusion caused by these errors. The corrected version of "On-Label/Off-Label Calculations for Druggable Mutations in Cancer" is now available, with the original version also provided for reference.The authors of the article in Cell (2018) have corrected two errors in their manuscript. First, in the STAR Methods section, under the subheading "Hypermutators and Immune Infiltrates," they incorrectly referred to Figures S7A-S7C for data on sample stratification by hypermutator status. The correct reference is Figure S6A-S6C. Second, the lists of highly frequent missense mutations for COAD (colon adenocarcinoma) and READ (rectum adenocarcinoma) in Figure S7 were incorrect. The authors mistakenly combined the two cancer types in their initial analysis, despite them being listed separately in the figure. After reordering the mutations by frequency for each cancer type independently, the information has been updated in the revised Figure S7. These errors did not affect the major conclusions of the paper and have been corrected online. The authors apologize for any confusion caused by these errors. The corrected version of "On-Label/Off-Label Calculations for Druggable Mutations in Cancer" is now available, with the original version also provided for reference.